Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.42 |
| ▸ | SRC | P12931 | 3/20 | 0.42 |
| ▸ | FLT3 | P36888 | 7/20 | 0.39 |
| ▸ | KIT | P10721 | 4/20 | 0.39 |
| ▸ | FLT4 | P35916 | 3/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.38 |
| ▸ | AURKA | O14965 | 3/20 | 0.38 |
| ▸ | MET | P08581 | 2/20 | 0.38 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.38 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2117620 | 0.94 | LRRK2 (0.40) | KDRPDGFRBFGFR1SRCTLK2 | |
| SCHEMBL2116293 | 0.90 | PDGFRB (0.43) | KDRPDGFRBFGFR1SRCEGFR | |
| SCHEMBL2116265 | 0.90 | PIM1 (0.39) | KDRPDGFRBFGFR1SRCFLT3 | |
| SCHEMBL2114214 | 0.85 | ALK (0.44) | KDRPDGFRBFGFR1SRCFLT3 | |
| SCHEMBL2114261 | 0.85 | CCNB2 (0.42) | KDRPDGFRBFGFR1SRCKIT | |
| SCHEMBL2116258 | 0.79 | CCNB2 (0.40) | KDRPDGFRBFGFR1SRCFLT3 | |
| SCHEMBL2117379 | 0.77 | KDR (0.42) | KDRPDGFRBFGFR1SRCKIT | |
| SCHEMBL397251 | 0.76 | FLT3 (0.46) | KDRPDGFRBFLT3KITFLT4 | |
| SCHEMBL397416 | 0.73 | NTRK1 (0.51) | KDRSRCFLT3KITFLT4 | |
| SCHEMBL393968 | 0.72 | NTRK1 (0.44) | KDRSRCFLT3KITFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2012-04-19 | — | — | US | disclosed |
| EP-1536783-B1 | SOLID FORMULATIONS COMPRISING AN INDOLINONE COMPOUND | PFIZER ITALIA SRL (IT) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | KDR 395/4885PDGFRB 555/4885FGFR1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.